Treatment modifiers and predictors of risperidone response in dementia: An individual participant data meta‐analysis of six randomized controlled trials

INTRODUCTION Risperidone is approved for behaviors and psychological symptoms of dementia (BPSD), despite modest efficacy and known risks. Identifying responsive symptoms, treatment modifiers, and predictors is crucial for personalized treatment. METHOD A one‐stage individual participant data meta‐analysis of six randomized controlled trials (risperidone: n = 1009; placebo: N = 712) was conducted. Mixed‐effects models assessed treatment effects, modifiers, and predictors, with BPSD measured via the Behavioral Pathology in Alzheimer's Disease scale. RESULTS Risperidone showed modest 8 week benefits for aggression (standardized mean difference [SMD]: −0.22; p < 0.001), psychosis (SMD: −0.23; p = 0.001), and anxiety/phobias (SMD: −0.19; p = 0.014), but not for activity, affective, or sleep disturbances. Pharmacokinetic/pharmacodynamic‐related factors (e.g., body mass index, endocrine disease, race/ethnicity) potentially modified treatment effects. Week 2 response predicted week 8 improvement (odds ratio: 4.46; p < 0.001). DISCUSSION Risperidone provided symptom‐specific benefits in reducing aggression, psychosis, and anxiety/phobias. Week 2 response predicted treatment outcomes, while certain patient characteristics may modify treatment response. Further research is needed to optimize the benefit–risk balance and individualize treatment. Highlights Risperidone modestly reduces symptoms of psychosis, aggression, and anxiety/phobias. Risperidone shows no effect on activity, affective, or sleep disturbances. Patient factors (body mass index, endocrine disease, race/ethnicity) may affect response. Positive response by week 2 predicts significant improvement later.